jpad journal
IF 2023 : 8.5

AND option

OR option

Archives

Back to all journals

journal articles

SWINGS AND ROUNDABOUTS IN CNS DRUG BIOMARKERS

M.B. Isaac, S. Vamvakas

J Prev Alz Dis 2017;4(3):134-135

Despite substantial advances in the understanding of central nervous system (CNS) disorders, healthcare systems worldwide face an unprecedented challenge in dealing with the unmet needs in this area (1). Meanwhile, the CNS drug pipeline looks worryingly dry. There are several reasons for this, including the obvious complexity of the CNS, a lack of interdisciplinary collaborations, increased drug development costs and the higher risk of clinical failure of CNS drugs, compared with those in other areas of drug development. The year 2016 was also disappointing in terms of failed trials of Alzheimer’ Dementia (AD) drugs.

CITATION:
M.B. Isaac ; S. Vamvakas (2017): Swings and Roundabouts in CNS Drug Biomarkers. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2017.18

Download PDFView HTML